A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Trial Details

NCT ID
NCT06057935
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pemetrexed
  • Cisplatin
  • Carboplatin
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932

Key Eligibility Criteria

  • Patient age 18 years or older, both sexes.
  • Clinical diagnosis of MPM at enrolling institution.
  • Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution.
  • Complete or near-complete CRS achieved.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →